NCT01120223 - Safety and Efficacy of LEO 80185 Gel in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

August 31, 2012

Study Completion Date

October 31, 2012

Conditions

Scalp Psoriasis

Interventions

DRUG

LEO 80185 (Xamiol® gel/Taclonex® Scalp topical suspension)

Once daily application

Trial Locations (17)

42055

CHU Saint-Etienne - Hôpital Nord, Service de Dermatologie, Saint-Etienne

T2G 1B1

Kirk Barber Research, Calgary

R3C 0N2

Winnipeg Clinic Dermatology Research, Winnipeg

L4M 6L2

UltraNova Skincare, Barrie

N6A 3H7

The Guenther Dermatology Research Centre, London

L3P 1A8

Lynderm Research Inc., Markham

K9J 1Z2

SKiN Centre for Dermatology, Peterborough

L4B 1A5

The Centre for Dermatology and Cosmetic Surgery, Richmond Hill

S7N 0W8

Royal University Hospital, Division of Dermatology, Saskatoon

ML6 0JS

Monklands Hospital, Airdrie

LE10 2SE

Burbage Surgery, Burbage

E11 1NR

Whipps Cross University Hospital, Leytonstone

M6 8HD

Hope Hospital, Salford

HG2 7SX

Harrogate District Hospital, Harrogate

LS1 3EX

Leeds General Infirmary, Leeds

B18 7QH

City Hospital, Birmingham

NP20 2UB

Royal Gwent Hospital, Newport